Evidence map›Paper›PMID 35821197›Full record

ArticleOncogenesis2022

MicroRNA-21 is immunosuppressive and pro-metastatic via separate mechanisms.

Lap Hing Chi, Ryan S N Cross, Richard P Redvers, Melissa Davis, Soroor Hediyeh-Zadeh, Suresh Mathivanan, Monisha Samuel, Erin C Lucas, Kellie Mouchemore, Philip A Gregory and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogenesis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Integrating multi-omics data for next-generation cancer research and precision medicine.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Lap Hing Chi *Olivia Newton-John Cancer Research Institute, HeidelbergVIC, Australia.ORCID http://orcid.org/0000-0003-0983-3474
Ryan S N Cross *Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Richard P RedversOlivia Newton-John Cancer Research Institute, HeidelbergVIC, Australia.
Melissa DavisBioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Soroor Hediyeh-ZadehBioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Suresh MathivananDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-7290-5795
Monisha SamuelDivision of Immunology and Allergy, Department of Medicine, Karolinska Institute, Solna, Sweden.
Erin C LucasImmunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0003-3577-7605
Kellie MouchemoreOlivia Newton-John Cancer Research Institute, HeidelbergVIC, Australia.
Philip A GregoryCentre for Cancer Biology, University of South Australia, Adelaide, SA, Australia.
Cameron N JohnstoneOlivia Newton-John Cancer Research Institute, HeidelbergVIC, Australia.
Robin L AndersonOlivia Newton-John Cancer Research Institute, HeidelbergVIC, Australia. robin.anderson@onjcri.org.au.ORCID http://orcid.org/0000-0002-6841-7422
Walter and Eliza Hall Institute of Medical Research · AULa Trobe University · AUOlivia Newton-John Cancer Wellness & Research Centre · AUThe University of Melbourne · AUKarolinska Institutet · SEUniversity of South Australia · AU

Funding

Department of Health | National Health and Medical Research Council (NHMRC) APP1020280
6 · The paper itself

Abstract

MiR-21 was identified as a gene whose expression correlated with the extent of metastasis of murine mammary tumours. Since miR-21 is recognised as being associated with poor prognosis in cancer, we investigated its contribution to mammary tumour growth and metastasis in tumours with capacity for spontaneous metastasis. Unexpectedly, we found that suppression of miR-21 activity in highly metastatic tumours resulted in regression of primary tumour growth in immunocompetent mice but did not impede growth in immunocompromised mice. Analysis of the immune infiltrate of the primary tumours at the time when the tumours started to regress revealed an influx of both CD4

Identifiers

PMID35821197
PMCPMC9276829
OpenAlexW4285094618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.